The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Mefloquine. The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Risedronate. The serum concentration of Ursodeoxycholic acid can be decreased when it is combined with Aluminum hydroxide. Quinapril may increase the hypotensive activities of Amifostine. The serum concentration of Chlorphenamine can be increased when it is combined with Stiripentol. The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalapril. Azelastine may decrease the excretion rate of Netilmicin which could result in a higher serum level. The serum concentration of Dienogest can be decreased when it is combined with Pentobarbital. Azidocillin may increase the anticoagulant activities of Phenindione. Formoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. The serum concentration of Proscillaridin can be increased when it is combined with Amodiaquine. Defibrotide may increase the anticoagulant activities of Fibrinolysin. Levofloxacin may increase the hypoglycemic activities of Glipizide. The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Niflumic Acid. The serum concentration of Nafamostat can be increased when it is combined with Probenecid. The metabolism of Montelukast can be decreased when combined with Efavirenz. The risk or severity of adverse effects can be increased when Antipyrine is combined with Tenofovir disoproxil. The risk or severity of adverse effects can be increased when Fentanyl is combined with Pimozide. The serum concentration of Gefitinib can be increased when it is combined with Darunavir. The metabolism of Estrone can be decreased when combined with Atazanavir. The risk or severity of adverse effects can be increased when Betamethasone is combined with Hepatitis A Vaccine. The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Meclizine. The risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin. The metabolism of Umeclidinium can be decreased when combined with Clemastine. The risk or severity of adverse effects can be increased when Morphine is combined with Bisoprolol. Oxprenolol may increase the hypotensive activities of Obinutuzumab. Dihydrotestosterone may increase the hypoglycemic activities of Empagliflozin. Vecuronium may increase the anticholinergic activities of Aclidinium. The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Hexobarbital. Metolazone may increase the hypotensive activities of Polythiazide. Magnesium salicylate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. Verapamil may increase the neuromuscular blocking activities of Atracurium besylate. Metamizole may increase the hyperkalemic activities of Drospirenone. The metabolism of Rosuvastatin can be decreased when combined with Losartan. The metabolism of Tacrolimus can be decreased when combined with Terbinafine. The metabolism of Methylprednisolone can be decreased when combined with Delavirdine. The serum concentration of Indinavir can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Tiotropium is combined with Pentazocine. The risk or severity of adverse effects can be increased when Levosimendan is combined with Chlorothiazide. The metabolism of Terbinafine can be decreased when combined with Atazanavir. Oxyphenonium may increase the anticholinergic activities of Tiotropium. The risk or severity of adverse effects can be increased when Fentanyl is combined with Lorcaserin. The risk or severity of adverse effects can be increased when Ramipril is combined with Epirizole. The metabolism of Tolbutamide can be decreased when combined with Topiramate. Proscillaridin may decrease the cardiotoxic activities of Veliparib. Dulaglutide may increase the hypoglycemic activities of Tolbutamide. The metabolism of Brivaracetam can be increased when combined with Secobarbital. The therapeutic efficacy of Polythiazide can be decreased when used in combination with Piroxicam. Mesalazine may decrease the antihypertensive activities of Benazepril. The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Flibanserin. Brimonidine may increase the antihypertensive activities of Candesartan cilexetil. The metabolism of Diazepam can be decreased when combined with Darunavir. Prednisone may increase the fluid retaining activities of Dihydrotestosterone. Aloxiprin may increase the anticoagulant activities of Citric Acid. Candoxatril may increase the hypotensive activities of Xylometazoline. Dihydroergotamine may increase the hypertensive activities of Apraclonidine. Goserelin may increase the QTc-prolonging activities of Ofloxacin. The metabolism of Trimipramine can be increased when combined with Hexobarbital. The metabolism of Prasterone can be decreased when combined with Bortezomib. The metabolism of Propoxyphene napsylate can be decreased when combined with Verapamil. The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Dopamine. The metabolism of Ixazomib can be decreased when combined with Pyrimethamine. The risk or severity of adverse effects can be increased when Lacidipine is combined with Papaverine. The metabolism of Phenylbutazone can be decreased when combined with Floxuridine. Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Timolol. The metabolism of Brompheniramine can be decreased when combined with Citalopram. The metabolism of Nortriptyline can be increased when combined with Amobarbital. The serum concentration of Pazufloxacin can be decreased when it is combined with Quinapril. Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Flunisolide can be decreased when combined with Telithromycin. The risk or severity of adverse effects can be increased when Solifenacin is combined with Heroin. Zileuton may decrease the antihypertensive activities of Metipranolol. The risk or severity of adverse effects can be increased when Salicylamide is combined with Indobufen. The metabolism of Enasidenib can be decreased when combined with Efavirenz. The risk or severity of adverse effects can be increased when Scopolamine is combined with Tolterodine. Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Brimonidine. Mesalazine may increase the hypoglycemic activities of Metformin. The metabolism of Selexipag can be decreased when combined with Darunavir. The risk or severity of adverse effects can be increased when Indapamide is combined with Proscillaridin. The serum concentration of Prasterone sulfate can be decreased when it is combined with Pentobarbital. Framycetin may increase the respiratory depressant activities of Atracurium besylate. The metabolism of Flunisolide can be decreased when combined with Indinavir. The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Orciprenaline. Moricizine may increase the hypotensive activities of Opium. The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketobemidone. Diclofenac may decrease the antihypertensive activities of Landiolol. The risk or severity of adverse effects can be increased when Olopatadine is combined with Phenylbutazone. The serum concentration of Dienogest can be decreased when it is combined with Primidone. The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone. Caroxazone may increase the hypoglycemic activities of Sitagliptin. The serum concentration of Estradiol can be decreased when it is combined with Siltuximab. Naproxen may decrease the antihypertensive activities of Talinolol. The serum concentration of Methotrexate can be increased when it is combined with Piroxicam. Sulindac may decrease the antihypertensive activities of Atenolol. Diethylstilbestrol may decrease the anticoagulant activities of Protein C. The metabolism of Dextroamphetamine can be decreased when combined with Manidipine. The metabolism of Romidepsin can be decreased when combined with Efavirenz. The risk or severity of adverse effects can be increased when Calcium Phosphate is combined with Dihydrotachysterol. The metabolism of Nortriptyline can be decreased when combined with Irbesartan. The metabolism of Thiabendazole can be decreased when combined with Ticlopidine. Sulfadiazine may increase the hypoglycemic activities of Pentamidine. The metabolism of Iloperidone can be decreased when combined with Cyclosporine. The metabolism of Flunisolide can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Indapamide. Carbaspirin calcium may decrease the antihypertensive activities of Arotinolol. Celiprolol may increase the hypotensive activities of Manidipine. The metabolism of Oxycodone can be decreased when combined with Bupropion. The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tenofovir disoproxil. The metabolism of Terfenadine can be decreased when combined with Pyrimethamine. Safrazine may increase the hypotensive activities of Moexipril. The metabolism of Cocaine can be decreased when combined with Dihydroergotamine. Oxaprozin may decrease the antihypertensive activities of Timolol. Estradiol may decrease effectiveness of Capromab pendetide as a diagnostic agent. Hydracarbazine may increase the hypoglycemic activities of Dapagliflozin. The therapeutic efficacy of Biperiden can be decreased when used in combination with Mefloquine. The serum concentration of Estradiol can be decreased when it is combined with Sitagliptin. The risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethylmorphine. The metabolism of Hexobarbital can be decreased when combined with Posaconazole. Brimonidine may increase the antihypertensive activities of Bimatoprost. Secobarbital may increase the hypotensive activities of Isocarboxazid. Procaterol may increase the hypokalemic activities of Bendroflumethiazide. Caroxazone may increase the anticholinergic activities of Doxylamine. The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Valdecoxib. The serum concentration of Pioglitazone can be decreased when it is combined with Vemurafenib. The metabolism of Solifenacin can be decreased when combined with Haloprogin. The serum concentration of Darunavir can be decreased when it is combined with Dasabuvir. The metabolism of Fluticasone furoate can be decreased when combined with Nilotinib. The metabolism of Medroxyprogesterone acetate can be increased when combined with Phenobarbital. The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Methamphetamine. Bisoprolol may increase the vasoconstricting activities of Ergoloid mesylate.